On the stock market since 2013, it operates in the world of money and finance. Now — the numbers.
This is an established company with proven profits.
Revenue is spread across several business lines; no single line carries the company.
An average decline of 81% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
The stock trades below its recent peak — about 9% off the top. A pullback, not a collapse.
It pays out $1.97 per share each year — regular cash for whoever holds the stock.
Over the last 3 years, sales fell about 67% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The price action doesn’t yet back an upward turn.
On our five-subject report card, HGH sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: HGH is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.